{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:12:30Z","timestamp":1791389550873,"version":"4.3.3"},"reference-count":24,"publisher":"American Society for Clinical Investigation","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,22]]},"abstract":"<jats:p>\n                    <jats:bold>BACKGROUND.<\/jats:bold>\n                    Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%; there are no FDA-approved treatments for AA. We previously identified a dominant IFN-\u03b3 transcriptional signature in cytotoxic T lymphocytes (CTLs) in human and mouse AA skin and showed that treatment with JAK inhibitors induced durable hair regrowth in mice by targeting this pathway. Here, we investigated the use of the oral JAK1\/2 inhibitor ruxolitinib in the treatment of patients with moderate-to-severe AA.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>METHODS.<\/jats:bold>\n                    We initiated an open-label clinical trial of 12 patients with moderate-to-severe AA, using oral ruxolitinib, 20 mg twice per day, for 3\u20136 months of treatment followed by 3 months follow-up off drug. The primary endpoint was the proportion of subjects with 50% or greater hair regrowth from baseline to end of treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS.<\/jats:bold>\n                    Nine of twelve patients (75%) demonstrated a remarkable response to treatment, with average hair regrowth of 92% at the end of treatment. Safety parameters remained largely within normal limits, and no serious adverse effects were reported. Gene expression profiling revealed treatment-related downregulation of inflammatory markers, including signatures for CTLs and IFN response genes and upregulation of hair-specific markers.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION.<\/jats:bold>\n                    In this pilot study, 9 of 12 patients (75%) treated with ruxolitinib showed significant scalp hair regrowth and improvement of AA. Larger randomized controlled trials are needed to further assess the safety and efficacy of ruxolitinib in the treatment of AA.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>TRIAL REGISTRATION.<\/jats:bold>\n                    Clinicaltrials.gov NCT01950780.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>FUNDING.<\/jats:bold>\n                    Locks of Love Foundation, the Alopecia Areata Initiative, NIH\/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the Irving Institute for Clinical and Translational Research\/Columbia University Medical Center Clinical and Translational Science Award (CUMC CTSA).\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.89790","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T11:01:06Z","timestamp":1474455666000},"source":"Crossref","is-referenced-by-count":255,"title":["Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata"],"prefix":"10.1172","volume":"1","author":[{"given":"Julian","family":"Mackay-Wiggan","sequence":"first","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8559-7314","authenticated-orcid":true,"given":"Ali","family":"Jabbari","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Cerise","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Ulerio","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Furniss","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Christiano","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"},{"name":"Department of Genetics and Development, Columbia University, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Clynes","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4065\/70.7.628"},{"issue":"2","key":"B2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","article-title":"Alopecia areata update: part II. Treatment","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.048"},{"issue":"2","key":"B4","article-title":"Interventions for alopecia areata","author":"Delamere","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature09114"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.073"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.03.036"},{"issue":"11","key":"B9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/archdermatol.2009.264","article-title":"Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study","volume":"145","author":"Strober","year":"2009","journal-title":"Arch Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.10.645"},{"issue":"4","key":"B11","article-title":"Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis","author":"Mart\u00ed-Carvajal","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13758"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis","volume":"2014","author":"Hsu","year":"2014","journal-title":"J Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.25"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12517"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2165\/11588080-000000000-00000"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.260"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23871"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.02.015"},{"issue":"15","key":"B23","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"2 Pt 1","key":"B24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0190-9622(99)70195-7","article-title":"Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation","volume":"40","author":"Olsen","year":"1999","journal-title":"J Am Acad Dermatol"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/89790\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:22:33Z","timestamp":1779200553000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/89790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":24,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2016,9,22]]},"published-print":{"date-parts":[[2016,9,22]]}},"alternative-id":["10.1172\/jci.insight.89790"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.89790","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726820264.793544504","asserted-by":"object"}]},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]},"article-number":"e89790"}}